Name: Ace Inhibitors in Hypertension: A Guide for General Practitioners (en Inglés)
SKU: 58603894
Price: 1164.82 MXN
Availability: InStock
Author: Strube, G.
ISBN: 9789401057370

portada Ace Inhibitors in Hypertension: A Guide for General Practitioners (en Inglés)

Ace Inhibitors in Hypertension: A Guide for General Practitioners (en Inglés)

Formato

Libro Físico

Autor

G. Strube

Editorial

Springer

Idioma

Inglés

N° páginas

107

Encuadernación

Tapa Blanda

Dimensiones

23.4x15.6x0.6 cm

Peso

0.17 kg.

ISBN13

9789401057370

Categorías

Medicina general y de familia
Medicina cardiovascular
Farmacología

Ace Inhibitors in Hypertension: A Guide for General Practitioners (en Inglés)

G. Strube (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 13 a 18 días háb.

$ 2,117.86$ 1,164.82

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 1,164.82

¡Envío Gratis! Llega entre el 25 Sep y el 05 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Ace Inhibitors in Hypertension: A Guide for General Practitioners (en Inglés)"

ACE inhibitors are one of the most exciting and interesting of recent medical developments. They fit the patho-physiologica1 processes of cardiovascular disease with fascinating precision and are a constant stimulus to the acquisition of greater understanding of the mechanisms involved and of the mode of action of the drugs themselves. There is still much to be learned, especially about the wider effects of the drugs, their precise mode and site of action and about differences between the different preparations. ACE inhibitors are of proven benefit to patients with chronic congestive heart failure and are the latest in the series of drugs used in the treatment of hypertension. Interest in the treatment of hypertension has paralleled the development of hypotensive drugs and the realisation that long-term prognosis could be significantly improved. The treatment of hypertension has progressed in stages following the development of a succession of increasingly effective drugs, each allowing a greater proportion of patients to be treated with fewer and fewer side-effects. First, the ganglion-blocking agents such as hexamethonium and guan- ethidine transformed the outlook for patients with malignant hypertension but proved too unpleasant for routine use in other forms of hypertension.